AR-102

AR-102 has inhibitory activity towards Staphylococcus aureus. AR-102 exhibits a competitive potent inhibition of the F98Y mutant DHFR (Ki = 0.22 nM) . AR-102 has been determined as ternary complex with NADPH in both wild-type S. aureus DHFR and the TMP-resistant F98Y mutant enzyme[1].

955005-63-7

12352211

Bacterial; Dihydrofolate reductase (DHFR)

Anti-infection; Metabolic Enzyme/Protease

COVID-19-immunoregulation

Infection

O[C@@H](C1=CC2=CC=CC=C2S1)CC[C@@H]3[C@H]([C@H](C[C@H]3O)O)CCCCCCC(OCC(CO)(CO)CO)=O

C28H42O8S

538.69

[1]Oefner, C., et al., (2009) . Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus. Acta crystallographica. Section D, Biological crystallography, 65 (Pt 8), 751–757.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19885/

Reference compound1

No Development Reported